Sinotherapeutics Inc. (SHA:688247)

Market Cap	4.66B +4.7%
Revenue (ttm)	480.48M +7.0%
Net Income	98.59M -10.0%
EPS	0.21 -9.2%
Shares Out	449.00M
PE Ratio	49.00
Forward PE	n/a
Dividend	0.05 (0.49%)
Ex-Dividend Date	Oct 21, 2025

Volume	3,270,961
Average Volume	3,991,873
Open	10.73
Previous Close	10.73
Day's Range	10.47 - 10.73
52-Week Range	8.49 - 13.28
Beta	0.10
RSI	49.54
Earnings Date	Apr 30, 2026

About Sinotherapeutics

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 312
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688247

Financial Performance

In 2024, Sinotherapeutics's revenue was 511.62 million, an increase of 70.61% compared to the previous year's 299.87 million. Earnings were 127.70 million, an increase of 109.09%.